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Background
Failure to efficiently degrade the DNA of apoptotic cells
activates innate immunity, by induction of TNFά and
IFNb production, causing chronic arthritis. If deficient,
DNase I could leed to accumulation of undigested DNA
which induce activation of phagocytes and production
of proinflammatory cytokines, notably TNF.
Aim
Disease outcome in JIA patients after one year of treat-
ment with TNFά therapy and their DNase I levels.
Methods
The study was performed in 25 JIA patients who
donated paired serum samples prior and one year after
continous etanercept therapy. Basic clinical data (six
core set variables defined in ACR PEDI outcome score)
were recorded along with alkalyne DNase I serum levels
using the method where acid soluble nucleotides are
determined spectrophotometrically at 260 nm. Treat-
ment schedule of etanercept was 0,4mg/kg body weight
subcutaneously twice weekly.
Results
JIA patients mean age was 14,7+/-4,22 and disease dura-
tion is 6,59+/- 2,76. Disease type distribution was 8%
systemic, 28% polyarticular RF-, 25% polyarticular RF+,
17% ERA and 21% extended oligoarticular JIA. Summary
of data results prior and after anti TNFά therapy: ESR
26,88 vs.15,52 (p<0,01); patientVAS 40,24 vs.24,40
(p<0,05); physicianVAS 38,08 vs.10,32 (p<0,01); CHAQ
0,674 vs.0,375 (p<0,01); LOM 15,52 vs. 11,68 (NS); AA
9,24 vs.2,64 (p<0,01). DNase I levels were significantly
lower prior (2.934 U/l) compared to values after one
year therapy (4,184 U/l; p<0,01). We have found correla-
tion between DNase I levels and AA (r=-0,993 p<0,5)
and other clinical outcome variables prior and after
therapy.
Conclusion
JIA patients with active disease have decreased DNase I
levels. Our results indicate significant increase of DNase
I in the sera of JIA patients after one year of anti TNFά
therapy which was associated to the disease clinical
improvement.
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